Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A parasitic disease caused by the protozoa, Entamoeba histolytica, mainly occurring in tropical regions after the ingestion of an amoebic cyst, and resulting in clinical manifestations that may range from an asymptomatic state to amoebic colitis (violent abdominal pain, a painful contracted feeling around the anal sphincter, blood and mucus in the stools but without the presence of fever), or amoebic liver abscesses (fever, chills, abdominal pain, weight loss, hepatomegaly) that can be fatal if not immediately treated. Extraintestinal involvement elsewhere (i.e. thoracic, hepatic) is extremely rare.
Features include sometimes findings: Weight loss, Diarrhea, Abdominal pain, and Gastrointestinal dysmotility and others; and rarely findings: Congestive heart failure, Abnormal membrane around the heart (abnormal pericardium morphology), Low red blood cell count (anemia), and Fever and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 9 | Diarrhea, Abdominal pain, Gastrointestinal dysmotility |
Biomarker and diagnostic research for amoebiasis due to Entamoeba histolytica has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for amoebiasis due to Entamoeba histolytica.
5 publications have been identified in PubMed for amoebiasis due to Entamoeba histolytica. Research spans Diagnostic / Biomarker (60%), Case Report / Case Series (20%), and Basic Science / Preclinical (20%).
Mujica R (2026). [PMID: 42086149](https://pubmed.ncbi.nlm.nih.gov/42086149/). *J Microbiol Methods*. [Diagnostic / Biomarker]
Abed ZM (2025). [PMID: 40747509](https://pubmed.ncbi.nlm.nih.gov/40747509/). *Iran J Parasitol*. [Diagnostic / Biomarker]
Sharma S (2025). [PMID: 40835601](https://pubmed.ncbi.nlm.nih.gov/40835601/). *Nat Commun*. [Basic Science / Preclinical]
Yagüe Parada Á (2025). [PMID: 39559918](https://pubmed.ncbi.nlm.nih.gov/39559918/). *Rev Esp Enferm Dig*. [Case Report / Case Series]
Datta P (2025). [PMID: 40471554](https://pubmed.ncbi.nlm.nih.gov/40471554/). *Trans R Soc Trop Med Hyg*. [Diagnostic / Biomarker]
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:36 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Heart and blood vessels | 4 | Chest pain, Congestive heart failure, Abnormal membrane around the heart (abnormal pericardium morphology) |
Lungs and breathing | 4 | Dyspnea, Pleural effusion, Pleural empyema |
Blood and immune system | 2 | Low red blood cell count (anemia), Elevated white blood cell count (increased total leukocyte count) |
Lab test results | 2 | Elevated circulating hepatic transaminase concentration, Elevated circulating alkaline phosphatase concentration |
Growth and development | 1 | Weight loss |
Metabolism | 1 | Fever |